Company launches Dynamic GLP-1 network to fuel clinical research

Atlanta, Georgia, United States-based healthcare data ecosystem OMNY Health has launched a groundbreaking Glucagon-Like Peptide-1 (GLP-1) data network featuring data from over 600,000 patients. The innovative network aims to enhance clinical research by providing comprehensive insights into the use of GLP-1 therapies across various patient demographics and social determinants of health (SDOH).

This move is meant to further establish OMNY Health's commitment to democratizing healthcare data and fostering cross-industry partnerships to drive research and innovation.

How does it work?

The newly launched GLP-1 data network by OMNY Health is built from a diverse array of electronic medical records (EMR) representing over 645,000 patients. It captures a wide range of demographic details, such as age, race/ethnicity, region of care delivery, and provider and payer types. By curating data from a broad spectrum of patient experiences, OMNY Health supports life sciences companies, healthcare systems, and AI-driven tech partners in gaining deeper insights into GLP-1 therapies.

Two recent studies leveraged this data to address knowledge gaps around GLP-1 use, including its application in pediatric populations and its impact on patients affected by SDOH factors.

For instance, one study focused on pediatric patients, revealing a 594.4% increase in GLP-1 prescriptions for children and adolescents from 2020 to 2023. The study found that the median age of users was 16 years, with a majority being female (72%).

By providing access to such detailed and diverse data, OMNY Health helps partner companies refine their clinical trials and treatment strategies, ensuring they are more inclusive and effective.

Why does it matter?

This initiative is significant because it addresses the glaring underutilization of healthcare data. Despite the vast amounts of data generated daily, around 97% of it remains unused, which is particularly problematic given the rising use of GLP-1 agonists for treating conditions like type 2 diabetes and obesity. As the demand for these medications grows, there is an urgent need for robust data to evaluate their effectiveness and long-term impacts on other conditions, such as cardiovascular and liver diseases.

"GLP-1 therapies are transforming the treatment landscape across multiple conditions beyond diabetes and obesity in profound ways," says Dr. Mitesh Rao, CEO of OMNY Health.

The systemic impact of these medications makes comprehensive data vital to fully understanding their effects on diverse patient populations. By facilitating data sharing between life sciences companies and healthcare providers, OMNY Health is enabling more in-depth research and potentially revolutionary advancements in patient care.

The context

The launch of OMNY Health's GLP-1 data network comes at a time when there is increasing recognition of the need for inclusive and comprehensive healthcare data. Many patient populations remain underrepresented in clinical research, leading to less effective treatment outcomes. The importance of understanding social determinants of health (SDOH) has also become more apparent, with studies showing that factors like economic insecurity, food insecurity, and social isolation can account for up to 50% of the variation in health outcomes in the United States.

With its new data network, OMNY Health is positioning itself at the forefront of addressing these gaps.

As Dr. Sameer Badlani from Fairview Health Services notes, "We are able to deliver more equitable clinical outcomes when the research is backed by data from diverse populations."

By incorporating diverse data points, especially those that consider SDOH, the network empowers researchers to better understand and address the complexities of patient care.